By combining the measures of serum Aβ aggregates, p-tau-AT8 aggregates and ASC specks together we built a composite biomarker profile defined as a ratio of the sum of the number of p-tau-AT8 aggregates and ASC specks to the number Aβ aggregates, (p-tau-AT8 + ASC) / Aβ (Fig. 3B), which was increased 6.2-fold in early AD and 11.7-fold at later stage (AD with dementia) and could distinguish early AD from control serum with an accuracy of 92% (AUC = 92%) and AD moderate dementia from control with an accuracy of 95% (AUC = 95%) (Fig. 3E). This evidence concerns the gene MAPT and Alzheimer disease.